Filing Details
BioNexus Gene Lab Corp (NASDAQ:BGLC) filed a Form 8-K with the Securities and Exchange Commission on October 07, 2026, disclosing a material event.
8k filedNASDAQ:BGLC
BioNexus Gene Lab Corp (BGLC) Reports Material Event to SEC
BioNexus Gene Lab Corp (NASDAQ:BGLC) filed a Form 8-K with the Securities and Exchange Commission on October 07, 2026, disclosing a material event.
At publication ·
What changed
BioNexus Gene Lab Corp (NASDAQ:BGLC) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- BioNexus Gene Lab Corp filed a Form 8-K with the SEC on October 7, 2026, disclosing a material event requiring shareholder attention.
- The company's stock trades at $1.34 with a market capitalization of $7.5 million as a healthcare company.
- Form 8-K filings report material events such as leadership changes, agreements, acquisitions, or asset sales between regular reports.
- The specific nature of the disclosed event determines its significance for the stock and investor decision-making.
Market Context
BioNexus Gene Lab Corp's stock currently trades at $1.34 with a market capitalization of $7.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for BioNexus Gene Lab Corp's stock.
All SEC filings for BioNexus Gene Lab Corp are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View BGLC Stock Page
Frequently Asked Questions
Where can I read BGLC's SEC filings?
Browse all filings on our BGLC SEC filings page.
What types of SEC filings does BioNexus Gene Lab Corp file?
Public companies like BioNexus Gene Lab Corp file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
